Literature DB >> 2620947

Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations.

S Bhatnagar, P Y Guru, J C Katiyar, R Srivastava, A Mukherjee, M S Akhtar, M Seth, A P Bhaduri.   

Abstract

A total of 51 imidazoles, pyrroles, quinolines and isoxazolines compounds were screened for antileishmanial activity in vivo and in vitro, using Leishmania donovani as the test parasite. The screening revealed hitherto unknown antileishmanial activity in these heterocycles. Three of the compounds screened (one belonging to isoxazoline series and two from pyrrole series) showed significant anti-leishmanial activity, ranging from 86-91 per cent inhibition in hamsters. When tested in vitro, using macrophage amastigote culture system, these compounds showed inhibition of 62-78 per cent at 30 micrograms/ml concentration.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2620947

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN： 0971-5916            Impact factor:   2.375


  6 in total

1.  Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.

Authors:  Nishi Shakya; Shraddha A Sane; Suman Gupta
Journal:  Parasitol Res       Date:  2011-01-07       Impact factor: 2.289

2.  Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy.

Authors:  R Pal; S Y Rizvi; B Kundu; K B Mathur; J C Katiyar
Journal:  Experientia       Date:  1991-05-15

3.  Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.

Authors:  Brajendra Tiwari; Richa Pahuja; Pradeep Kumar; Srikanta Kumar Rath; Kailash Chand Gupta; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Leishmania donovani Dipeptidylcarboxypeptidase Inhibitor as a Potential Oral Treatment for Visceral Leishmaniasis.

Authors:  Karthik Ramalingam; Sonali Gangwar; Deep Chandra Balodi; Apeksha Anand; Shailendra Yadav; Subhasish Biswas; Anil Kumar Karunakaran Sasikala; Kailash Chand Gupta; Sanjay Batra; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2022-07-19       Impact factor: 5.938

Review 5.  Visceral leishmaniasis: experimental models for drug discovery.

Authors:  Suman Gupta
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

Review 6.  A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis.

Authors:  Emily Rose Mears; Farrokh Modabber; Robert Don; George E Johnson
Journal:  PLoS Negl Trop Dis       Date:  2015-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.